This study is testing a medication called praliciguat in adults with focal segmental glomerulosclerosis (FSGS), a kidney disease. Researchers want to see if praliciguat can help reduce protein in your urine, which is a sign of kidney damage. You would either receive praliciguat or a placebo (an inactive pill) for 24 weeks. After that, all participants will receive praliciguat for another 24 weeks. To join, you must be 18 or older, have a certain level of protein in your urine (UPCR ≥1 g/g), and be taking specific blood pressure medications (ACEi or ARB). Your kidney function also needs to be at a certain level (eGFR ≥25). The study aims to enroll 60 participants, but its current recruitment status is unclear.

Study design

This is a Phase 2 study, meaning it's an early-stage trial. It's randomized, double-blind, and placebo-controlled, involving about 60 participants.

What's involved

You would take an oral tablet (either praliciguat or placebo) for an initial 24 weeks, followed by praliciguat for an additional 24 weeks. The primary measurement is taken at the start and up to Week 24.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome is measured up to Week 24. All participants will receive praliciguat for an additional 24 weeks after the initial treatment period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.